Did I miss an announcement?, page-101

First 101 Last

Share
Profile

Follow
zeeb0t

2,012 Posts.

565

20/07/20

18:57

Post #: 45989604
Share

Originally posted by SallySet: ↑

Hilarious. Typos and talking to a friend. Don't think the company is impressive? Have you seen what the new CEO achieved in the latest quarterly? See ASX Ann.

DXN has a very professional presence on the internet. Google DXN Limited and watch a bit of the transparency - Sydney Data Centre, Perth fabrication centre etc.

This coming from a DW8 investor waiting for the 4.5 cent party? You do know total revenues for DW8 in the March 2020 quarterly were below $80,000? My local pizza shop does triple this. And by the way, I think DW8 have less than $500,000 cash, so if they don't raise before next quarterly announcement - less than three weeks away - it would be a bigger surprise to me than the Donald becoming President. Congrats on signing up that Kombucha drink company and Henscke Btw. Huge inroads. And why are the DW8 crowd so quiet on the innovative distribution centre? Albury/Wondonga ?

I doubt Leading Edge have spare capacity to compete on the NSW tender as they are focused on finishing Newcastle. DXN have up to 55 module spare capacity at Perth.

I've listed the new CEO achievements at DXN ad museum on these threads, as verified by the ASX announcements.

DXN has spent $7 million plus on Sydney Olympic Park. $2.9 million on Tasmania. $7 million on Melbourne. Perth Manufacturing Facility Asset. Contracted revenue going into FY2021 is approx $3 million and increasing. Approx profit is $1 million.

DXN module build work for FY2020 is $7 million. My estimate is for at least $3 million cash at bank.

For a $33 million market cap, tangible assets, cash at bank, revenues and growth are all impressive - see ASX announcements.

Congrats to all holders. So much jealousy and envy!

Expand

Hey SallySet, are you still with us?

DXN Price at posting: 2.2¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 6 more messages in this thread...

First 101 Last

Add DXN (ASX) to my watchlist

(20min delay)
Last 8.9¢		Change 0.004(4.71%)		Mkt cap ! $16.82M

Open	High	Low	Value	Volume
8.5¢	9.0¢	8.5¢	$27.98K	317.3K

Buyers (Bids)

No.	Vol.	Price($)
1	1235	8.8¢

Sellers (Offers)

Price($)	Vol.	No.
9.1¢	3949	1

View Market Depth

No.	Vol.	Price($)
1	6238	0.089
1	1235	0.088
2	102683	0.086
2	349999	0.085
1	54787	0.084

Price($)	Vol.	No.
0.090	12500	1
0.091	3949	1
0.092	42578	2
0.095	63333	2
0.096	189000	2

Last trade - 11.41am 04/10/2024 (20 minute delay)

DXN (ASX) Chart

Did I miss an announcement?, page-101

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Did I miss an announcement?, page-101

Top Stories

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News